News | October 02, 2007

Avid Holds Trial for Imaging Compound

October 3, 2007 - Avid Radiopharmaceuticals Inc., a product-focused molecular imaging company, announced today that enrollment has begun in a proof-of-concept phase I clinical trial investigating Avid’s development compound 18F-AV-133 for imaging patients with movement disorders, including Parkinson’s Disease (PD) and essential tremor and dementias, including Dementia with Lewy Bodies (DLB) and Alzheimer’s Disease (AD).

The compound, used with positron emission tomography (PET) imaging, targets vesicular monoamine transporters (VMAT2) in the brain and may enable more accurate and earlier diagnosis of neurodegenerative diseases. This new imaging compound may thus lead to improved disease management for patients and their caregivers. The study will be initially conducted at the University of Michigan and will involve 30 patients.

Avid’s 18F-AV-133 compound may also be useful for improved management of Alzheimer’s Disease (AD) because up to 25 percent of AD patients also have a component of PD or DLB. The goal of this initial trial is to determine whether 18F-AV-133 PET imaging can detect losses in nigrostriatal neurons in the brains of patients with AD, PD and DLB. Patients with overlapping symptoms and disease pathology are often misdiagnosed today.

The VMAT2 study represents the second clinical stage program in Avid’s development pipeline. The company, founded in 2004, is currently conducting a phase one clinical trial of its PET amyloid imaging compound for early detection of AD.

For more information: www.avidrp.com

Related Content

Guerbet, IBM Watson Health Partner on Artificial Intelligence for Liver Imaging
News | Clinical Decision Support | July 10, 2018
Guerbet announced it has signed an exclusive joint development agreement with IBM Watson Health to develop an...
Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
OptiStar Elite injector
Feature | Contrast Media Injectors | March 07, 2018 | Grand View Research Inc.
The global contrast media injectors market is expected to reach $1.4 billion by 2025, growing at a compound annual...
TriHealth in Cincinnati

TriHealth in Cincinnati.

Sponsored Content | Case Study | Contrast Media Injectors | March 06, 2018
The continuing search for advantages to improve workflow has radiology departments constantly searching for new...
Guerbet Presents Contrast&Care Injection Management Solution at ECR 2018
News | Contrast Media | February 28, 2018
February 28, 2018 — Guerbet will present its new Contrast&Care application, as well as other...
A brain MRI. Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns. Gadolinium deposition in the brain has raised concerns about Gadolinium toxicity.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Feature | Magnetic Resonance Imaging (MRI) | February 16, 2018 | Dave Fornell
One of the biggest concerns in radiology in recent years is the safety of gadolinium-based contrast agents (GBCAs) us
ACR Introduces New Contrast Reaction Card
News | Contrast Media | February 07, 2018
The American College of Radiology (ACR) introduced a new contrast reaction card that summarizes important steps to be...
Bracco Diagnostics' MultiHance Contrast Agent Earns Expanded Approval for Pediatric MRI
News | Contrast Media | January 30, 2018
Bracco Diagnostics Inc. announced the labeling of its contrast agent MultiHance has obtained U.S. Food and Drug...
Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec
Overlay Init